Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
暂无分享，去创建一个
H. Groen | R. V. van Klaveren | N. Pavlakis | F. Schramel | P. Baas | J. Burgers | S. Gans | A. Nowak | A. Vincent | W. Buikhuisen | J. A. Burgers | J. H. Schouwink | C. Korse | F. Custers | W. Strankinga | F. Custers | J. Schouwink